Cited by 445Lung Cancer Treatments and MutationsMelanoma and MAPK PathwaysHER2/EGFR in Cancer Research

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1

Open access

Ohashi, Kadoaki, Sequist, Lecia V., Arcila, Maria E., Moran, Teresa, Chmielecki, Juliann, Lin, Ya-Lun, Pan, Yumei, Wang, Lu, de Stanchina, Elisa, Shien, Kazuhiko, Aoe, Keisuke, Toyooka, Shinichi, Kiura, Katsuyuki, Fernandez-Cuesta, Lynnette, Fidias, Panos, Yang, James Chih-Hsin, Miller, Vincent A., Riely, Gregory J., Kris, Mark G., Engelman, Jeffrey A., Vnencak-Jones, Cindy L., Dias-Santagata, Dora, Ladanyi, Marc, Pao, William·2012·Proceedings of the National Academy of Sciences

DOI 10.1073/pnas.1203530109PMC PMC3411967

Open this paper in CoChat — free account Open PDF

Abstract

Acquired resistance to EGF receptor (EGFR) tyrosine kinase inhibitors (TKIs) is inevitable in metastatic EGFR-mutant lung cancers. Here, we modeled disease progression using EGFR-mutant human tumor cell lines. Although five of six models displayed alterations already found in humans, one harbored an unexpected secondary NRAS Q61K mutation; resistant cells were sensitive to concurrent EGFR and MEK inhibition but to neither alone. Prompted by this finding and because RAS/RAF/MEK mutations are known mediators of acquired resistance in other solid tumors (colon cancers, gastrointestinal stromal tumors, and melanomas) responsive to targeted therapies, we analyzed the frequency of secondary KRAS/NRAS/BRAF/MEK1 gene mutations in the largest collection to date of lung cancers with acquired resistance to EGFR TKIs. No recurrent NRAS, KRAS, or MEK1 mutations were found in 212, 195, or 146 patient samples, respectively, but 2 of 195 (1%) were found to have mutations in BRAF (G469A and V600E). Ectopic expression of mutant NRAS or BRAF in drug-sensitive EGFR-mutant cells conferred resistance to EGFR TKIs that was overcome by addition of a MEK inhibitor. Collectively, these positive and negative results provide deeper insight into mechanisms of acquired resistance to EGFR TKIs in lung cancer and inform ongoing clinical trials designed to overcome resistance. In the context of emerging knowledge about mechanisms of acquired resistance to targeted therapies in various cancers, our data highlight the notion that, even though solid tumors share common signaling cascades, mediators of acquired resistance must be elucidated for each disease separately in the context of treatment.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1073/pnas.1203530109

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Self-citation
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Self-citation
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
Self-citation
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
Self-citation
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681
Self-citation
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
Shigematsu, H., Lin, L., Takahashi, T., Nomura, M., Suzuki, M., Wistuba, I. I., Fong, K. M., Lee, H., Toyooka, S., Shimizu, N., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji055 · Cited by 2,377
Self-citation

Show all 42 references

Research works printed but not linked: 4

10.1371/journal.pmed.0020073 · DOI · Paper page
10.1126/scitranslmed.3002003 · DOI · Paper page
10.1158/1078-0432.CCR-06-0714 · DOI
10.1242/dmm.003681 · DOI

Sorted by citations

Items 101–200 of 445

Drug Resistance to EGFR Inhibitors in Lung Cancer
Tetsu, O., Hangauer, M. J., Phuchareon, J., Eisele, D. W., & McCormick, F. P. (2016) · Chemotherapy · doi:10.1159/000443368 · Cited by 88
Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature
Zhou, C., & Yao, L. D. (2015) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.10.002 · Cited by 87
Trisubstituted Imidazoles with a Rigidized Hinge Binding Motif Act As Single Digit nM Inhibitors of Clinically Relevant EGFR L858R/T790M and L858R/T790M/C797S Mutants: An Example of Target Hopping
Juchum, M., Günther, M., Döring, E., Sievers‐Engler, A., Lämmerhofer, M., & Laufer, S. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00178 · Cited by 84
The Impact of Microenvironmental Heterogeneity on the Evolution of Drug Resistance in Cancer Cells
Mumenthaler, S. M., Foo, J., Choi, N. C., Heise, N., Leder, K., Agus, D. B., Pao, W. J., Michor, F., & Mallick, P. (2015) · Cancer Informatics · doi:10.4137/cin.s19338 · Cited by 83
Self-citation
Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA
Re, M. D., Tiseo, M., Bordi, P., D’Incecco, A., Camerini, A., Petrini, I., Lucchesi, M., Inno, A., Spada, D., Vasile, E., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.6957 · Cited by 85
The integrated stress response is tumorigenic and constitutes a therapeutic liability in KRAS-driven lung cancer
Ghaddar, N., Wang, S., Woodvine, B., Krishnamoorthy, J., van Hoef, V., Darini, C., Kazimierczak, U., Ah-son, N., Popper, H. H., Johnson, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24661-0 · Cited by 85
Targeted therapies in development for non-small cell lung cancer
Dy, G. K., & Reungwetwattana, T. (2013) · Journal of Carcinogenesis · doi:10.4103/1477-3163.123972 · Cited by 80
Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors
Rolfo, C. D., Giovannetti, E., Hong, D. S., Bivona, T. G., Raez, L. E., Bronte, G., Buffoni, L., Reguart, N., Santos, E. S., Germonpré, P. R., et al. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.05.009 · Cited by 80
Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy
Re, M. D., Crucitta, S., Gianfilippo, G., Passaro, A., Petrini, I., Restante, G., Michelucci, A., Fogli, S., de Marinis, F., Porta, C., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20163951 · Cited by 84
Therapeutic Strategies Utilized in the Setting of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors
Yu, H. A., Riely, G. J., & Lovly, C. M. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2437 · Cited by 80
Self-citation
The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients
Rachiglio, A. M., Fenizia, F., Piccirillo, M. C., Galetta, D., Crinò, L., Vincenzi, B., Barletta, E., Pinto, C., Ferraù, F., Lambiase, M., et al. (2019) · Cancers · doi:10.3390/cancers11030341 · Cited by 76
Inhibition of DCLK1 sensitizes resistant lung adenocarcinomas to EGFR-TKI through suppression of Wnt/β-Catenin activity and cancer stemness
Yan, R., Fan, X., Xiao, Z., Liu, H., Huang, X., Liu, J., Zhang, S., Yao, J., An, G., & Ge, Y. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.01.030 · Cited by 75
MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib
Huang, M.-H., Lee, J., Chang, Y., Tsai, H.-H., Lin, Y., Lin, A. M.-Y., & Yang, J. C. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.09.002 · Cited by 74
Self-citation
Current Approaches in NSCLC Targeting K-RAS and EGFR
Aran, V., & Omerović, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225701 · Cited by 74
A genetic cell context-dependent role for ZEB1 in lung cancer
Zhang, T., Guo, L., Creighton, C. J., Lü, Q., Gibbons, D. L., Yi, E. S., Deng, B., Molina, J. R., Sun, Z., Yang, P., et al. (2016) · Nature Communications · doi:10.1038/ncomms12231 · Cited by 73
Loss of MIG6 Accelerates Initiation and Progression of Mutant Epidermal Growth Factor Receptor–Driven Lung Adenocarcinoma
Maity, T. K., Venugopalan, A., Linnoila, I., Cultraro, C. M., Giannakou, A., Nemati, R., Zhang, X., Webster, J. D., Ritt, D., Ghosal, S., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0750 · Cited by 73
ALK-rearrangements and testing methods in non-small cell lung cancer: a review
Shackelford, R. E., Vora, M., Mayhall, K., & Cotelingam, J. D. (2014) · Genes & Cancer · doi:10.18632/genesandcancer.3 · Cited by 72
Drug resistance mechanisms and progress in the treatment of EGFR‑mutated lung adenocarcinoma (Review)
Sun, R., Hou, Z., Zhang, Y., & Jiang, B. (2022) · Oncology Letters · doi:10.3892/ol.2022.13528 · Cited by 77
The expression of V-ATPase is associated with drug resistance and pathology of non-small-cell lung cancer
Lü, Q., Lu, S., Huang, L., Wang, T., Wan, Y., Zhou, C. X., Zhang, C., Zhang, Z., & Li, X. (2013) · Diagnostic Pathology · doi:10.1186/1746-1596-8-145 · Cited by 68
A high-content image-based method for quantitatively studying context-dependent cell population dynamics
Garvey, C. M., Spiller, E. R., Lindsay, D., Chiang, C.-T., Choi, N. C., Agus, D. B., Mallick, P., Foo, J., & Mumenthaler, S. M. (2016) · Scientific Reports · doi:10.1038/srep29752 · Cited by 69
A genetic interaction analysis identifies cancer drivers that modify EGFR dependency
Liao, S., Davoli, T., Leng, Y., Li, M. Z., Xu, Q., & Elledge, S. J. (2017) · Genes & Development · doi:10.1101/gad.291948.116 · Cited by 67
The resistance mechanisms and treatment strategies for EGFR -mutant advanced non-small-cell lung cancer
Zhong, W., Zhou, Q. H., & Wu, Y.-L. L. C. (2017) · Oncotarget · doi:10.18632/oncotarget.20311 · Cited by 66
Mechanisms of resistance to EGFR targeted therapies
Hrustanovic, G., Lee, B. J., & Bivona, T. G. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.23627 · Cited by 67
Targeting oncogenic drivers in lung cancer: Recent progress, current challenges and future opportunities
Yoda, S., Dagogo‐Jack, I., & Hata, A. N. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.08.007 · Cited by 68
Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives
Tomasello, C., Baldessari, C., Napolitano, M., Orsi, G., Grizzi, G., Bertolini, F., Barbieri, F., & Cascinu, S. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.01.013 · Cited by 65
KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma
Kadota, K., Sima, C. S., Arcila, M. E., Hedvat, C. V., Kris, M. G., Jones, D. R., Adusumilli, P. S., & Travis, W. D. (2016) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000744 · Cited by 63
Self-citation
A BRAF new world
Frisone, D., Friedlaender, A., Malapelle, U., Banna, G. L., & Addeo, A. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103008 · Cited by 65
Review of the current targeted therapies for non-small-cell lung cancer
Nguyen, K.-S. H. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i4.576 · Cited by 62
Gefitinib resistance resulted from STAT3-mediated Akt activation in lung cancer cells
Wu, K., Chang, Q., Lu, Y., Qiu, P., Chen, B., Thakur, C., Sun, J., Li, L., Kowluru, A., & Chen, F. (2013) · Oncotarget · doi:10.18632/oncotarget.1431 · Cited by 62
Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer
Barnes, T. A., O'Kane, G. M., Vincent, M. D., & Leighl, N. B. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00113 · Cited by 61
Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor
Romaniello, D., Marrocco, I., Nataraj, N. B., Ferrer, I., Garcia, D. D., Vaknin, I., Oren, R., Lindzen, M., Ghosh, S., Kreitman, M., et al. (2020) · Cancers · doi:10.3390/cancers12092394 · Cited by 63
Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition
Lou, W., Chen, Y., Zhu, K., Deng, H., Wu, T., & Wang, J. (2017) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b17-00271 · Cited by 62
Small-molecule EGFR tyrosine kinase inhibitors for the treatment of cancer
Lee, C., Shiao, H., Wang, W.-C., & Hsieh, H. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.928283 · Cited by 60
The emerging roles of NGS-based liquid biopsy in non-small cell lung cancer
Zhang, Y.-C., Zhou, Q. H., & Wu, Y.-L. L. C. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0536-6 · Cited by 60
Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer
Wang, Z., Xing, Y., Li, B., Li, X., Liu, B., & Wang, Y. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00107-x · Cited by 62
ERK pathway agonism for cancer therapy: evidence, insights, and a target discovery framework
Timofeev, O. N., Giron, P., Lawo, S., Pichler, M., & Noeparast, A. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00554-5 · Cited by 63
Cetuximab Attenuates Its Cytotoxic and Radiosensitizing Potential by Inducing Fibronectin Biosynthesis
Eke, I., Storch, K., Krause, M., & Cordes, N. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0344 · Cited by 63
Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients
Ko, R., Kenmotsu, H., Serizawa, M., Koh, Y., Wakuda, K., Ono, A., Taira, T., Naito, T., Murakami, H., Isaka, M., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2902-0 · Cited by 59
RAS–MAPK Reactivation Facilitates Acquired Resistance in FGFR1 -Amplified Lung Cancer and Underlies a Rationale for Upfront FGFR–MEK Blockade
Bockorny, B., Rusan, M., Chen, W., Liao, R. G., Li, Y. Y., Piccioni, F., Wang, J., Tan, L., Thorner, A. R., Li, T., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0464 · Cited by 61
Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer.
Savas, P. S., Hughes, B. G. M., & Solomon, B. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2013.08.52 · Cited by 59
Drug Resistance to Molecular Targeted Therapy and Its Consequences for Treatment Decisions in Non-Small-Cell Lung Cancer
Spaans, J. N., & Goss, G. D. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00190 · Cited by 57
A Phase 1/2 Trial of Ruxolitinib and Erlotinib in Patients with EGFR -Mutant Lung Adenocarcinomas with Acquired Resistance to Erlotinib
Yu, H. A., Perez, L., Chang, Q., Gao, S. P., Kris, M. G., Riely, G. J., & Bromberg, J. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.08.140 · Cited by 58
Self-citation
Mechanisms of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance and Strategies to Overcome Resistance in Lung Adenocarcinoma
Chang, Y. S., Choi, C., & Lee, J. C. (2016) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2016.79.4.248 · Cited by 59
Linking Tumor Mutations to Drug Responses via a Quantitative Chemical–Genetic Interaction Map
Martins, M. M., Zhou, A. Y., Corella, A. N., Horiuchi, D., Yau, C. S. F., Rakhshandehroo, T., Gordan, J. D., Levin, R. S., Johnson, J. R., Jascur, J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0552 · Cited by 55
YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics
Fan, P., Narzisi, G., Jayaprakash, A. D., Venturini, E., Robine, N., Smibert, P., Germer, S., Yu, H. A., Jordan, E., Paik, P. K., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1717782115 · Cited by 56
Self-citation
Diagnostic significance of cerebrospinal fluid EGFR mutation analysis for leptomeningeal metastasis in non-small-cell lung cancer patients harboring an active EGFR mutation following gefitinib therapy failure
Sasaki, S., Yoshioka, Y., Ko, R., Katsura, Y., Namba, Y., Shukuya, T., Kido, K., Iwakami, S., Tominaga, S., & Takahashi, K. (2015) · Respiratory Investigation · doi:10.1016/j.resinv.2015.07.001 · Cited by 53
Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistancePreprint
Jia, P., Jin, H., Meador, C. B., Xia, J., Ohashi, K., Liu, L., Pirazzoli, V., Dahlman, K. B., Politi, K. A., Michor, F., et al. (2013) · Genome Research · doi:10.1101/gr.152322.112 · Cited by 54
Self-citation
Recent updates on the resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors and resistance reversion strategies in lung cancer
Tripathi, S. K., Pandey, K., Rengasamy, K. R. R., & Biswal, B. K. (2020) · Medicinal Research Reviews · doi:10.1002/med.21700 · Cited by 54
Targeting the Epidermal Growth Factor Receptor with Molecular Degraders: State-of-the-Art and Future Opportunities
Maity, P., Chatterjee, J., Patil, K. T., Arora, S., Katiyar, M. K., Kumar, M., Samarbakhsh, A., Joshi, G., Bhutani, P., Chugh, M., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01242 · Cited by 51
The induction of MIG6 under hypoxic conditions is critical for dormancy in primary cultured lung cancer cells with activating EGFR mutations
Endo, H., Okami, J., Okuyama, H., Nishizawa, Y., Imamura, F., & Inoue, M. (2017) · Oncogene · doi:10.1038/onc.2016.431 · Cited by 50
Overcoming resistance to EGFR tyrosine kinase inhibitors in lung cancer, focusing on non-T790M mechanisms
Suda, K., Rivard, C. J., Mitsudomi, T., & Hirsch, F. R. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1355243 · Cited by 49
Sym015: A Highly Efficacious Antibody Mixture against MET -Amplified Tumors
Poulsen, T. T., Grandal, M. M., Skartved, N. J. Ø., Hald, R., Alifrangis, L. H., Koefoed, K., Lindsted, T., Fröhlich, C., Pollmann, S. E., Eriksen, K. W., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0782 · Cited by 49
Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review
Karlsen, E., Kahler, S. L., Tefay, J., Joseph, S. R., & Simpson, F. (2021) · Cells · doi:10.3390/cells10051206 · Cited by 52
Mechanisms of resistance to irreversible epidermal growth factor receptor tyrosine kinase inhibitors and therapeutic strategies in non-small cell lung cancer
Xu, J., Wang, J., & Zhang, S. (2017) · Oncotarget · doi:10.18632/oncotarget.21164 · Cited by 52
Adaptive and Acquired Resistance to EGFR Inhibitors Converge on the MAPK Pathway
Ma, P., Fu, Y., Chen, M., Jing, Y., Wu, J., Li, K., Shen, Y. H., Gao, J., Wang, M., Zhao, X., et al. (2016) · Theranostics · doi:10.7150/thno.14409 · Cited by 48
Role of EGFR mutations in lung cancers: prognosis and tumor chemosensitivity
Suda, K., & Mitsudomi, T. (2015) · Archives of Toxicology · doi:10.1007/s00204-015-1524-7 · Cited by 47
Current Drugs and Drug Targets in Non-Small Cell Lung Cancer: Limitations and Opportunities
Daga, A., Ansari, A., Patel, S., Mirza, S., Rawal, R., & Umrania, V. V. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2015.16.10.4147 · Cited by 48
Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathways
Rothenberg, S. M., Concannon, K., Cullen, S. J., Boulay, G., Turke, A. B., Faber, A. C., Lockerman, E. L., Rivera, M. N., Engelman, J. A., Maheswaran, S., et al. (2015) · eLife · doi:10.7554/elife.06132 · Cited by 49
Self-citation
TOPK promotes lung cancer resistance to EGFR tyrosine kinase inhibitors by phosphorylating and activating c-Jun
Li, Y., Yang, Z., Li, W., Xu, S., Wang, T., Wang, T., Niu, M., Zhang, S., Jia, L., & Li, S. (2016) · Oncotarget · doi:10.18632/oncotarget.6826 · Cited by 46
Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma
Pirazzoli, V., Ayeni, D. O., Meador, C. B., Sanganahalli, B. G., Hyder, F., de Stanchina, E., Goldberg, S. B., Pao, W. J., & Politi, K. A. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0620 · Cited by 46
Self-citation
Acriflavine Inhibits Acquired Drug Resistance by Blocking the Epithelial-to-Mesenchymal Transition and the Unfolded Protein Response
Dekervel, J., Bulle, A. S., Windmolders, P., Lambrechts, D., Cutsem, E. V., Verslype, C., & van Pelt, J. F. (2016) · Translational Oncology · doi:10.1016/j.tranon.2016.11.008 · Cited by 46
MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib
Ninomiya, K., Ohashi, K., Makimoto, G., Tomida, S., Higo, H., Kayatani, H., Ninomiya, T., Kubo, T., Ichihara, E., Hotta, K., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-20326-z · Cited by 45
Self-citation
CD44 Facilitates Epithelial-to-Mesenchymal Transition Phenotypic Change at Acquisition of Resistance to EGFR Kinase Inhibitors in Lung Cancer
Suda, K., Murakami, I., Yu, H., Kim, J., Tan, A. C., Mizuuchi, H., Rozeboom, L. M., Ellison, K. E., Rivard, C. J., Mitsudomi, T., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1279 · Cited by 46
Investigate the mechanisms of Chinese medicine Fuzhengkangai towards EGFR mutation-positive lung adenocarcinomas by network pharmacology
Bing, Z., Cheng, Z., Shi, D., Liu, X., Tian, J., Yao, X., Zhang, J., Wang, Y., & Yang, K. (2018) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-018-2347-x · Cited by 45
Mutational and network level mechanisms underlying resistance to anti-cancer kinase inhibitors
Mancini, M., & Yarden, Y. (2015) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2015.09.018 · Cited by 45
Quantitative Profiling of Protein Tyrosine Kinases in Human Cancer Cell Lines by Multiplexed Parallel Reaction Monitoring Assays
Kim, H., Lin, D., Lee, H., Li, M., & Liebler, D. C. (2015) · Molecular & Cellular Proteomics · doi:10.1074/mcp.o115.056713 · Cited by 44
Effect of dasatinib on EMT-mediated-mechanism of resistance against EGFR inhibitors in lung cancer cells
Sesumi, Y., Suda, K., Mizuuchi, H., Kobayashi, Y., Sato, K., Chiba, M., Shimoji, M., Tomizawa, K., Takemoto, T., & Mitsudomi, T. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.12.012 · Cited by 44
Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations
Lou, N.-N., Zhang, X., Chen, H., Zhou, Q. H., Yan, L., Xie, Z., Su, J., Chen, Z., Tu, H., Yan, H., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11218 · Cited by 43
Self-citation
Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion
Monica, S. L., Minari, R., Cretella, D., Bonelli, M. A., Fumarola, C., Cavazzoni, A., Galetti, M., Digiacomo, G., Riccardi, F., Petronini, P. G., et al. (2019) · Targeted Oncology · doi:10.1007/s11523-019-00669-x · Cited by 43
Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy
Zhao, Y., Wang, H., & He, C. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03828-8 · Cited by 45
Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient
Ribeiro, M. F. S. A., Knebel, F. H., Bettoni, F., Saddi, R., Sacardo, K. P., Canedo, F. S. N. A., Alessi, J. V. M., Shimada, A. K., Marin, J. F. G., Camargo, A. A., et al. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00149-4 · Cited by 42
Successes and Limitations of Targeted Cancer Therapy in Lung Cancer
Suda, K., & Mitsudomi, T. (2014) · Progress in tumor research · doi:10.1159/000355902 · Cited by 43
Dynamic Reprogramming of Signaling Upon Met Inhibition Reveals a Mechanism of Drug Resistance in Gastric Cancer
Lai, A. Z., Cory, S. M., Zhao, H., Gigoux, M., Monast, A., Guiot, M.-C., Huang, S., Tofigh, A., Thompson, C., Naujokas, M. A., et al. (2014) · Science Signaling · doi:10.1126/scisignal.2004839 · Cited by 44
Tumor heterogeneity: evolution through space and time in EGFR mutant non small cell lung cancer patients.
Majem, M., & Remón, J. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2013.03.09 · Cited by 41
Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non‐small cell lung cancer
Sacher, A. G., Janne, P. A., & Oxnard, G. R. (2014) · Cancer · doi:10.1002/cncr.28723 · Cited by 42
The EGFR T790M Mutation Is Acquired through AICDA-Mediated Deamination of 5-Methylcytosine following TKI Treatment in Lung Cancer
Kadi, N. E., Wang, L., Davis, A., Körkaya, H., Cooke, A., Vadnala, V., Brown, N. A., Betz, B. L., Cascalho, M., Kalemkerian, G. P., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3370 · Cited by 41
Self-citation
Genotype Driven Therapy for Non-Small Cell Lung Cancer: Resistance, Pan Inhibitors and Immunotherapy
Singh, S. S., Dahal, A., Shrestha, L., & Jois, S. D. S. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190222183219 · Cited by 42
EGF Induced RET Inhibitor Resistance inCCDC6-RETLung Cancer Cells
Chang, H. K., Sung, J. H., Moon, S. U., Kim, H.-S., Kim, J. W., & Lee, J. S. (2016) · Yonsei Medical Journal · doi:10.3349/ymj.2017.58.1.9 · Cited by 40
Heterogeneity and mutation in KRAS and associated oncogenes: evaluating the potential for the evolution of resistance to targeting of KRAS G12C
Cannataro, V. L., Gaffney, S. G., Stender, C., Zhao, Z.-M., Philips, M. R., Greenstein, A. E., & Townsend, J. P. (2018) · Oncogene · doi:10.1038/s41388-017-0105-z · Cited by 43
Second-line treatment of EGFR T790M-negative non-small cell lung cancer patients
Liao, B.-C., Griesing, S., & Yang, J. C. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919890286 · Cited by 40
Self-citation
Overcoming Resistance to Targeted Therapies in Cancer
Redmond, K. L., Papafili, A., Lawler, M., & Schaeybroeck, S. V. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.09.028 · Cited by 39
A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma Who Have Acquired Resistance to EGFR–Tyrosine Kinase Inhibitors
Han, J., Lee, K. H., Kim, S., Min, Y. J., Cho, E., Lee, Y., Lee, S.-H., Kim, H. Y., Lee, G. K., Nam, B., et al. (2016) · Cancer Research and Treatment · doi:10.4143/crt.2016.058 · Cited by 39
Dominant mechanisms of primary resistance differ from dominant mechanisms of secondary resistance to targeted therapies
Asić, K. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.08.004 · Cited by 38
Epithelial‐to‐mesenchymal transition in the context of epidermal growth factor receptor inhibition in non‐small‐cell lung cancer
Bronte, G., Bravaccini, S., Bronte, E., Burgio, M. A., Rolfo, C. D., Delmonte, A., & Crinò, L. (2018) · Biological reviews/Biological reviews of the Cambridge Philosophical Society · doi:10.1111/brv.12416 · Cited by 38
Impact of concurrent genomic alterations in epidermal growth factor receptor (EGFR)-mutated lung cancer
Gini, B., Thomas, N. J., & Blakely, C. M. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd.2020.03.78 · Cited by 38
Pharmacokinetics, Clinical Indications, and Resistance Mechanisms in Molecular Targeted Therapies in Cancer
Izar, B., Rotow, J. K., Gainor, J. F., Clark, J. W., & Chabner, B. A. (2013) · Pharmacological Reviews · doi:10.1124/pr.113.007807 · Cited by 38
IKBKE Is a Substrate of EGFR and a Therapeutic Target in Non–Small Cell Lung Cancer with Activating Mutations of EGFR
Challa, S., Guo, J.-P., Ding, X., Xu, C., Li, Y., Kim, D., Smith, M. A., Cress, W. D., Coppola, D., Haura, E. B., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0069 · Cited by 37
DNA terminal structure-mediated enzymatic reaction for ultra-sensitive discrimination of single nucleotide variations in circulating cell-free DNA
Wu, T., Chen, W., Yang, W., Tan, H., Wang, J., Xiao, X., Li, M., & Zhao, M. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx1218 · Cited by 37
Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors
Nurwidya, F., Takahashi, F., Murakami, A., Kobayashi, I., Kato, M., Shukuya, T., Tajima, K., Shimada, N., & Takahashi, K. (2013) · Respiratory Investigation · doi:10.1016/j.resinv.2013.07.007 · Cited by 37
Novel computational method for predicting polytherapy switching strategies to overcome tumor heterogeneity and evolution
Jönsson, V. D., Blakely, C. M., Lin, L., Asthana, S., Matni, N., Olivas, V. R., Pazarentzos, E., Gubens, M. A., Bastian, B. C., Taylor, B. S., et al. (2017) · Scientific Reports · doi:10.1038/srep44206 · Cited by 36
Current Strategies for Treating NSCLC: From Biological Mechanisms to Clinical Treatment
Li, J., & Kwok, H. F. (2020) · Cancers · doi:10.3390/cancers12061587 · Cited by 37
Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models
Corte, C. M. D., Ciaramella, V., Cardone, C., Monica, S. L., Alfieri, R. R., Petronini, P. G., Malapelle, U., Vigliar, E., Pepe, F., Troncone, G., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.02.025 · Cited by 36
Targeting MERTK and AXL in EGFR Mutant Non-Small Cell Lung Cancer
Yan, D., Earp, H. S., DeRyckere, D., & Graham, D. K. (2021) · Cancers · doi:10.3390/cancers13225639 · Cited by 35
Thymic neoplasm: a rare disease with a complex clinical presentation.
Rashid, O. M., Cassano, A. D., & Takabe, K. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2013.01.12 · Cited by 35
EGFR inhibition in non-small cell lung cancer: current evidence and future directions
Chi, A., Remick, S. C., & Tse, W. W. (2013) · Biomarker Research · doi:10.1186/2050-7771-1-2 · Cited by 35
Strategies to overcome resistance to tyrosine kinase inhibitors in non-small-cell lung cancer
Santarpía, M., Gil, N., & Rosell, R. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2015.1055252 · Cited by 34
Current and Future Approaches in the Management of Non–Small-Cell Lung Cancer Patients With Resistance to EGFR TKIs
Matikas, A., Mistriotis, D., Georgoulias, V., & Kotsakis, A. P. (2015) · Clinical Lung Cancer · doi:10.1016/j.cllc.2014.12.013 · Cited by 34
Molecular docking based screening of novel designed chalcone series of compounds for their anti-cancer activity targeting EGFR kinase domain
Rao, C. M. M. P., Yejella, R. P., Rehman, R., Basha, S. H., & Innovative Informatica Technologies, H. –. 5. 0. (2015) · Bioinformation · doi:10.6026/97320630011322 · Cited by 34
Genomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFR
Whitsett, T. G., Richer, A. L., Friel, J. M., Carson, V. M., & Inge, L. J. (2015) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s52845 · Cited by 35
The new concepts on overcoming drug resistance in lung cancer
Dong, X., Xu, C., Lei, P., & Zhang, W. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s60672 · Cited by 32

Authors: Ohashi, K., Sequist, L. V., Arcila, M. E., Moran, T., Chmielecki, J., Lin, Y.-L., Pan, Y., Wang, L., de Stanchina, E., Shien, K., Aoe, K., Toyooka, S., Kiura, K., Fernandez-Cuesta, L., Fidias, P., Yang, J. C.-H., Miller, V. A., Riely, G. J., Kris, M. G., Engelman, J. A., Vnencak-Jones, C. L., Dias-Santagata, D., Ladanyi, M., & Pao, W.
Affiliations: Vanderbilt University (US)
Harvard University (US)
Department of Pathology,
Catalan Institute of Oncology, Universitat Autonoma de Barcelona and Hospital Universitari Germans Trias i Pujol, 08916 Badalona, Barcelona, Spain;
Cornell University (US)
Anti-Tumor Assessment Core Facility, and
Okayama University Hospital (JP)
National Sanyo Hospital (JP)
Okayama University (JP)
Max Planck Institute for Neurological Research with Klaus Joachim Zülch Laboratories of the Max Planck Society and the Medical Faculty, Cologne 50931, Germany;
National Taiwan University (TW)
Memorial Sloan Kettering Cancer Center (US)
Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, 37232; and
ORCID: Ohashi, Kadoaki
Sequist, Lecia V.
Arcila, Maria E.
Chmielecki, Juliann
Wang, Lu
Shien, Kazuhiko
Toyooka, Shinichi
Kiura, Katsuyuki
Yang, James Chih-Hsin
Miller, Vincent A.
Riely, Gregory J.
Kris, Mark G.
Engelman, Jeffrey A.
Dias-Santagata, Dora
Ladanyi, Marc
Pao, William
Venue: Proceedings of the National Academy of Sciences
Publisher: National Academy of Sciences
Published: 2012-07-06
Volume: 109
Issue: 31
Pages: E2127-33
ISSN: 0027-8424 (ISSN-L)
1091-6490
DOI: 10.1073/pnas.1203530109
PMC: PMC3411967
OpenAlex: W2096540669
Cited by: 441
References: 42
Citations by year: 2026: 7 · 2025: 13 · 2024: 10 · 2023: 13 · 2022: 16 · 2021: 28 · 2020: 27 · 2019: 23 · 2018: 51 · 2017: 50 · 2016: 54 · 2015: 60 · 2014: 45 · 2013: 40 · 2012: 4
FWCI: 38.40
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Proceedings of the National Academy of Sciences (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Max Planck Institute for Plasma Physics (submittedVersion)
MPG.PuRe (Max Planck Society) (submittedVersion)
Funders: Bristol-Myers Squibb
Pfizer
AstraZeneca
GlaxoSmithKline
Celgene
Clovis Oncology
Agios Pharmaceuticals
Symphogen
U.S. Public Health Service (1R21-156000)
Foundation Medicine
National Cancer Institute (P30 CA 68485, R01CA121210, P01CA129243, CA90949, U54CA143798, P50CA090949, P30CA068485)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Keywords: EGFR tyrosine kinase inhibitors, acquired drug resistance, EGFR-mutant lung cancer, BRAF mutation, NRAS Q61K, KRAS mutation, MEK1 mutations, Ras/Raf/MEK signaling, MEK inhibitor combination, secondary mutations, metastatic lung cancer
MeSH terms: Clinical Trials as Topic, Female, Humans, Lung Neoplasms, Male, Proto-Oncogene Proteins, Proto-Oncogene Proteins p21(ras), ras Proteins, Drug Resistance, Neoplasm, Amino Acid Substitution, Mutation, Missense, Cell Line, Tumor, Protein Kinase Inhibitors, MAP Kinase Kinase 1, Proto-Oncogene Proteins B-raf, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks